Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4981 studies found for:    Immunodeficiency
Show Display Options
Rank Status Study
21 Active, not recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Other: Gene transfer
22 Terminated
Has Results
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Conditions: Growth Failure;   X-linked Severe Combined Immunodeficiency (XSCID);   Growth Hormone Resistence
Intervention: Drug: Increlex
23 Completed Stem Cell Gene Therapy to Treat X-Linked Severe Combined Immunodeficiency (XSCID)
Condition: Severe Combined Immunodeficiency
Intervention: Drug: Gene-Transduced Autologous CD34+ Stem Cells
24 Completed Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
Conditions: Agammaglobulinemia;   IgG Deficiency;   Common Variable Immunodeficiency
Intervention: Drug: Immunoglobulins Intravenous (Human)
25 Withdrawn A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
Condition: Human Immunodeficiency Virus-Type 1
Intervention: Drug: No intervention
26 Unknown  Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
Condition: Severe Combined Immunodeficiency
Intervention: Genetic: gene sequencing
27 Completed Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Conditions: Agammaglobulinemia;   IgG Deficiency;   Common Variable Immunodeficiency
Intervention: Drug: Immunoglobulins Intravenous (Human)
28 Not yet recruiting Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency
Intervention: Biological: TBX-1400
29 Unknown  Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
Conditions: Human Immunodeficiency Virus (HIV);   Tuberculosis (TB);   Latent Tuberculosis Infection (LTI)
Intervention: Drug: Isoniazid
30 Completed IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
Conditions: T-Cell Immune Deficiency Diseases;   Severe Combined Immunodeficiency
Intervention: Drug: Busulfan, Fludarabine and ATG
31 Recruiting Generalized Neonatal Screening of Severe Combined Immunodeficiencies
Condition: Severe Combined Immunodeficiency, Atypical
Intervention: Biological: SCID screening
32 Completed Transplantation of Hematopoietic Cells in Children With Severe Combined Immunodeficiency Syndrome
Condition: Severe Combined Immunodeficiency
Interventions: Procedure: Stem cell transplant;   Drug: Filgrastim, Alemtuzumab;   Device: Miltenyi CliniMACS
33 Not yet recruiting Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)
Condition: Combined Immunodeficiencies
Intervention: Biological: Depletion in CD45RA graft donor
34 Recruiting Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Condition: Inherited Immune Deficiencies
Interventions: Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
35 Completed Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms
Condition: Common Variable Immunodeficiency
Intervention:
36 Recruiting A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
Conditions: Hepatitis C Virus Infection;   Human Immunodeficiency Virus Infection;   Chronic Hepatitis C;   Compensated Cirrhosis and Non-cirrhotics
Intervention: Drug: ABT-493/ABT-530
37 Active, not recruiting Link4Health: A Combination Strategy for Linkage and Retention, Swaziland
Condition: HIV (Human Immunodeficiency Virus)
Interventions: Procedure: POC (point-of-care) CD4+ (cluster of differentiation 4) Count;   Procedure: Accelerated ART (antiretroviral therapy) Initiation;   Behavioral: Basic Care and Prevention Package;   Behavioral: Cellular Appointment Reminders and Follow-Up;   Other: Financial Incentive
38 Not yet recruiting IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
Condition: Primary Immunodeficiency
Intervention: Drug: IgHy10
39 Completed STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
Condition: Common Variable Immunodeficiency
Intervention: Drug: STA-5326
40 Completed Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
Conditions: Primary Immunodeficiency Disorders;   Immune Thrombocytopenic Purpura (ITP);   Kawasaki Syndrome
Intervention: Biological: Immune Globulin Intravenous (Human), 10%

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years